BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance
- PMID: 29256493
- DOI: 10.1038/nmeth.4535
BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance
Abstract
Poly(ADP-ribose) polymerase inhibition (PARPi) is a promising new therapeutic approach for the treatment of cancers that show homologous recombination deficiency (HRD). Despite the success of PARPi in targeting HRD in tumors that lack the tumor suppressor function of BRCA1 or BRCA2, drug resistance poses a major obstacle. We developed three-dimensional cancer organoids derived from genetically engineered mouse models (GEMMs) for BRCA1- and BRCA2-deficient cancers. Unlike conventional cell lines or mammospheres, organoid cultures can be efficiently derived and rapidly expanded in vitro. Orthotopically transplanted organoids give rise to mammary tumors that recapitulate the epithelial morphology and preserve the drug response of the original tumor. Notably, GEMM-tumor-derived organoids can be easily genetically modified, making them a powerful tool for genetic studies of tumor biology and drug resistance.
Similar articles
-
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.Cancer Discov. 2013 Jan;3(1):68-81. doi: 10.1158/2159-8290.CD-12-0049. Epub 2012 Oct 25. Cancer Discov. 2013. PMID: 23103855 Free PMC article.
-
BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.Cancer Res. 2015 Feb 15;75(4):732-41. doi: 10.1158/0008-5472.CAN-14-0839. Epub 2014 Dec 15. Cancer Res. 2015. PMID: 25511378
-
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.Clin Cancer Res. 2008 Jun 15;14(12):3916-25. doi: 10.1158/1078-0432.CCR-07-4953. Clin Cancer Res. 2008. PMID: 18559613
-
New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.Curr Treat Options Oncol. 2016 Mar;17(3):12. doi: 10.1007/s11864-015-0378-9. Curr Treat Options Oncol. 2016. PMID: 26931795 Free PMC article. Review.
-
Mechanisms of PARP inhibitor sensitivity and resistance.DNA Repair (Amst). 2018 Nov;71:172-176. doi: 10.1016/j.dnarep.2018.08.021. Epub 2018 Aug 23. DNA Repair (Amst). 2018. PMID: 30177437 Review.
Cited by
-
Shieldin and CST co-orchestrate DNA polymerase-dependent tailed-end joining reactions independently of 53BP1-governed repair pathway choice.Nat Struct Mol Biol. 2025 Jan;32(1):86-97. doi: 10.1038/s41594-024-01381-9. Epub 2024 Sep 3. Nat Struct Mol Biol. 2025. PMID: 39227718 Free PMC article.
-
Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.Cancer Med. 2021 Jan;10(1):119-134. doi: 10.1002/cam4.3578. Epub 2020 Oct 27. Cancer Med. 2021. PMID: 33107222 Free PMC article.
-
Single-Cell Transcriptomics Reveals Heterogeneity and Drug Response of Human Colorectal Cancer Organoids.Annu Int Conf IEEE Eng Med Biol Soc. 2018 Jul;2018:2378-2381. doi: 10.1109/EMBC.2018.8512784. Annu Int Conf IEEE Eng Med Biol Soc. 2018. PMID: 30440885 Free PMC article.
-
Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.Cancers (Basel). 2023 Feb 18;15(4):1299. doi: 10.3390/cancers15041299. Cancers (Basel). 2023. PMID: 36831640 Free PMC article. Review.
-
Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers.Front Oncol. 2020 May 5;10:670. doi: 10.3389/fonc.2020.00670. eCollection 2020. Front Oncol. 2020. PMID: 32432041 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous